First Look Analysts Research Calls for Thursday, April 13

Investing

24/7 Wall St. Staff

Published: April 13, 2023 8:09 am

This report was sent to Briefing.com subscribers earlier today.

Upgrades:

> Chevron (CVX) upgraded to Sector Outperform from Sector Perform at Scotiabank; tgt raised to $200

> DraftKings (DKNG) upgraded to Neutral from Underperform at Exane BNP Paribas; tgt $17

> EOG Resources (EOG) upgraded to Sector Outperform from Sector Perform at Scotiabank; tgt lowered to $145

> Merck (MRK) upgraded to Buy from Neutral at Citigroup; tgt raised to $130

> Steven Madden (SHOO) upgraded to Buy from Neutral at Citigroup; tgt raised to $42

> SunPower (SPWR) upgraded to Neutral from Underperform at BofA Securities; tgt raised to $15

> World Wrestling (WWE) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $120

> V.F. Corp (VFC) upgraded to Buy from Hold at Edward Jones

Downgrades:

> BRF SA (BRFS) downgraded to Underperform from Neutral at BofA Securities

> CubeSmart (CUBE) downgraded to Peer Perform from Outperform at Wolfe Research

> Exxon Mobil (XOM) downgraded to Sector Perform from Sector Outperform at Scotiabank; tgt lowered to $135

> First Solar (FSLR) downgraded to Hold from Buy at Deutsche Bank; tgt raised to $230

> LSB Industries (LXU) downgraded to Hold from Buy at Jefferies; tgt lowered to $10

> LyondellBasell (LYB) downgraded to Hold from Buy at Jefferies; tgt lowered to $90

> National Storage Affiliates (NSA) downgraded to Underperform from Peer Perform at Wolfe Research

> Playtika (PLTK) downgraded to Underperform from Neutral at BofA Securities; tgt $10

> POSCO (PKX) downgraded to Underweight from Neutral at JP Morganowngrades:

Others:

> Broadcom (AVGO) initiated with a Buy at The Benchmark Company; tgt $770

> CCC Intelligent Solutions (CCCS) initiated with an Overweight at JP Morgan; tgt $11

> Costco (COST) initiated with an Outperform at William Blair

> CRISPR Therapeutics (CRSP) initiated with an Overweight at Cantor Fitzgerald; tgt $72

> FTC Solar (FTCI) initiated with a Buy at H.C. Wainwright; tgt $5

> General Motors (GM) initiated with a Neutral at Mizuho; tgt $39

> Intellia Therapeutics (NTLA) initiated with a Buy at Canaccord Genuity; tgt $66

> Magnite (MGNI) initiated with a Buy at B. Riley Securities; tgt $15

> Pliant Therapeutics (PLRX) initiated with an Outperform at Robert W. Baird; tgt $44

> Primerica (PRI) initiated with a Strong Buy at Raymond James; tgt $244

> PubMatic (PUBM) initiated with a Buy at B. Riley Securities; tgt $20

> Relay Therapeutics (RLAY) initiated with an Outperform at Raymond James; tgt $29

> RxSight (RXST) initiated with an Outperform at Oppenheimer; tgt $23

> Strategic Education (STRA) resumed with a Neutral at BofA Securities; tgt $103

> Verve Therapeutics (VERV) initiated with a Buy at Canaccord Genuity; tgt $29

> Vital Farms (VITL) initiated with a Hold at Needham

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.